Suppr超能文献

重复肌钙蛋白测量对提高急诊科胸痛患者 HEART 评分安全性的价值。

Value of Repeated Troponin Measurements to Improve the Safety of the HEART Score for Chest Pain Patients at the Emergency Department.

机构信息

From the Julius Center for Health Sciences and Primary Care, Department of General Practice, University Medical Center Utrecht, Utrecht, The Netherlands.

Utrecht University, Faculty of Medicine, Utrecht, The Netherlands.

出版信息

Crit Pathw Cardiol. 2020 Jun;19(2):62-68. doi: 10.1097/HPC.0000000000000213.

Abstract

OBJECTIVE

The HEART score is a clinical decision support tool for physicians to stratify the risk of major adverse cardiac events (MACE) in patients presenting with chest pain at the emergency department. The score includes 5 elements, including troponin level. Our aim was to compare safety and efficiency of the HEART scores calculated by using the first representative troponin (ie, based on time since symptom onset) compared to the original HEART score, where calculation was based on the first available troponin measurement, irrespective of duration of symptoms.

METHODS

We performed a secondary analysis on patients from the HEART-impact trial (2013-2014, the Netherlands). Two HEART scores were calculated for all patients: a HEART score with a T (troponin) element score based on the first available troponin (HEART-first) and 1 with a T element score based on the first representative troponin (ie, at least 3 hours after symptom onset; HEART-representative). We compared all patients' scores and risk categories between HEART-first and HEART-representative. Furthermore, we compared safety (proportion of patients with MACE receiving a low score) and efficiency (proportion of patients with a low score) between HEART-first and HEART-representative.

RESULTS

We included 1222 patients. In 882 (72%) patients, the first troponin was representative, resulting in the same HEART-first and HEART-representative score. In the remaining 340 patients the use of HEART-representative led to a different score than HEART-first in 43 patients (3.5%). Out of the 222 patients with MACE, 11 patients (5.0%) received a low score by using HEART-first compared with 10 patients (4.5%) when using HEART-representative (P = 0.83). The number of patients with a low score was similar (P = 0.93) when using the HEART-first (464/1222; 38%) or HEART-representative score (462/1222; 38%).

CONCLUSIONS

Using a representative troponin measurement changed the value of the HEART score in only 3.5% of patients and had no impact on safety and efficiency of the HEART score. These results suggest there is no need to wait for a representative troponin measurement and should encourage physicians to adhere to the original HEART score guidelines.

摘要

目的

HEART 评分是一种临床决策支持工具,用于对急诊科胸痛患者进行主要不良心脏事件(MACE)风险分层。该评分包括 5 个要素,包括肌钙蛋白水平。我们的目的是比较基于首次代表性肌钙蛋白(即根据症状发作后的时间)计算的 HEART 评分与原始 HEART 评分的安全性和效率,其中原始 HEART 评分的计算基于首次获得的肌钙蛋白测量值,而不论症状持续时间如何。

方法

我们对 HEART-impact 试验(2013-2014 年,荷兰)中的患者进行了二次分析。为所有患者计算了两种 HEART 评分:一种是基于首次获得的肌钙蛋白的 HEART 评分(HEART-first),另一种是基于首次代表性肌钙蛋白的 T(肌钙蛋白)元素评分(即症状发作后至少 3 小时;HEART-representative)。我们比较了 HEART-first 和 HEART-representative 之间所有患者的评分和风险类别。此外,我们比较了 HEART-first 和 HEART-representative 之间的安全性(接受低评分的 MACE 患者比例)和效率(低评分患者比例)。

结果

我们纳入了 1222 名患者。在 882 名(72%)患者中,首次肌钙蛋白具有代表性,导致 HEART-first 和 HEART-representative 评分相同。在其余 340 名患者中,使用 HEART-representative 导致 43 名患者(3.5%)的评分与 HEART-first 不同。在 222 名 MACE 患者中,11 名患者(5.0%)使用 HEART-first 时获得低评分,而 10 名患者(4.5%)使用 HEART-representative 时获得低评分(P=0.83)。使用 HEART-first(464/1222;38%)或 HEART-representative 评分(462/1222;38%)时,获得低评分的患者数量相似(P=0.93)。

结论

仅在 3.5%的患者中,使用代表性肌钙蛋白测量值改变了 HEART 评分的价值,且对 HEART 评分的安全性和效率没有影响。这些结果表明,不需要等待代表性肌钙蛋白测量值,应鼓励医生遵守原始 HEART 评分指南。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验